Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
IsoRay Medical, Inc. Swedish Medical Center |
---|---|
Information provided by: | IsoRay Medical, Inc. |
ClinicalTrials.gov Identifier: | NCT00621413 |
The purpose of this study is to observe PSA response and incidence of side effects in patients diagnosed with intermediate to high risk prostate cancer and treated with Cesium-131 in combination of external beam therapy.
Condition |
---|
Prostate Cancer |
Study Type: | Observational |
Study Design: | Cohort, Prospective |
Official Title: | Dosimetric and Morbidity Outcomes of Cs-131 Brachytherapy in Combination With External Beam Radiation Therapy in Subjects With Intermediate to High Risk Adenocarcinoma of the Prostate: An Observational Study |
Estimated Enrollment: | 100 |
Study Start Date: | February 2007 |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Male |
Accepts Healthy Volunteers: | Yes |
Sampling Method: | Non-Probability Sample |
diagnosed patients with intermediate to high risk cancer of the prostate. Patient will be in a Radiation Oncology setting.
Inclusion Criteria:
Intermediate Risk prostate cancer as determined by the following:
High risk prostate cancer as determined by the following:
Exclusion Criteria:
Any hormonal blockade or therapy that:
United States, Arizona | |
Arizona Oncology Services Foundation | |
Phoenix, Arizona, United States, 85013 | |
United States, California | |
Eisenhower Medical Center | |
Rancho Mirage, California, United States, 92270 | |
Dorthory Schneider Cancer Center | |
San Mateo, California, United States, 94401 | |
United States, Massachusetts | |
Levine Cancer Center | |
Worcester, Massachusetts, United States, 01605 | |
United States, Nevada | |
St. Mary's Regional Medical Center | |
Reno, Nevada, United States, 89503 | |
United States, New York | |
Northshore Medical Accelerator | |
Smithtown, New York, United States, 11787 | |
United States, Virginia | |
Sentara Cancer Institute | |
Hampton, Virginia, United States, 23666 | |
United States, Washington | |
Seattle Prostate Institute / Swedish Hospital | |
Seattle, Washington, United States, 98104 | |
Virginia Mason Medical Center | |
Seattle, Washington, United States, 98101 |
Principal Investigator: | John Sylvester, MD | Seattle Prostate Institute / Swedish Hospital |
Principal Investigator: | Steve Kurtzman, MD | Mills Peninsula Hospital |
Responsible Party: | Seattle Prostate Institute / Mills Peninsula Hospital ( John Sylvester, MD / Steve Kurtzman, MD ) |
Study ID Numbers: | isoray_cs131_pc01 |
Study First Received: | February 12, 2008 |
Last Updated: | February 21, 2008 |
ClinicalTrials.gov Identifier: | NCT00621413 History of Changes |
Health Authority: | United States: Institutional Review Board |
prostate cancer intermediate risk high risk |
brachytherapy Cesium-131 seed brachytherapy intermediate and high risk cancer of the prostate |
Prostatic Diseases Genital Neoplasms, Male Urogenital Neoplasms |
Genital Diseases, Male Adenocarcinoma Prostatic Neoplasms |
Neoplasms Neoplasms by Site Prostatic Diseases Genital Neoplasms, Male |
Urogenital Neoplasms Genital Diseases, Male Prostatic Neoplasms |